Inflammasomes: a novel therapeutic target in pulmonary hypertension?

Pulmonary hypertension (PH) is a rare, progressive pulmonary vasculopathy characterized by increased mean pulmonary arterial pressure, pulmonary vascular remodelling and right ventricular failure. Current treatments are not curative, and new therapeutic strategies are urgently required. Clinical and...

Full description

Saved in:
Bibliographic Details
Published in:British journal of pharmacology 2019-06, Vol.176 (12), p.1880-1896
Main Authors: Scott, Tara Elizabeth, Kemp‐Harper, Barbara K, Hobbs, Adrian J
Format: Article
Language:English
Subjects:
Animals
Antihypertensive Agents - pharmacology
Blood pressure
Cytokines
Damage patterns
Heart
Humans
Hypertension
Hypertension, Pulmonary - drug therapy
Hypertension, Pulmonary - metabolism
Hypertension, Pulmonary - pathology
Inflammasomes
Inflammasomes - drug effects
Inflammasomes - metabolism
Inflammation
Inflammation - drug therapy
Inflammation - metabolism
Inflammation - pathology
Pulmonary hypertension
Review
Right ventricular failure
Themed Section: Review
Therapeutic applications
Vascular diseases
Ventricle
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pulmonary hypertension (PH) is a rare, progressive pulmonary vasculopathy characterized by increased mean pulmonary arterial pressure, pulmonary vascular remodelling and right ventricular failure. Current treatments are not curative, and new therapeutic strategies are urgently required. Clinical and preclinical evidence has established that inflammation plays a key role in PH pathogenesis, and recently, inflammasomes have been suggested to be central to this process. Inflammasomes are important regulators of inflammation, releasing the pro‐inflammatory cytokines IL‐1β and IL‐18 in response to exogenous pathogen‐ and endogenous damage‐associated molecular patterns. These cytokines are elevated in PH patients, but whether this is a consequence of inflammasome activation remains to be determined. This review will briefly summarize current PH therapies and their pitfalls, introduce inflammasomes and the mechanisms by which they promote inflammation and, finally, highlight the preclinical and clinical evidence for the potential involvement of inflammasomes in PH pathobiology and how they may be targeted therapeutically. Linked Articles This article is part of a themed section on Immune Targets in Hypertension. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.12/issuetoc
ISSN:0007-1188
1476-5381
DOI:10.1111/bph.14375